Published in J Inflamm Res on March 14, 2012
Prolonged niacin treatment leads to increased adipose tissue PUFA synthesis and anti-inflammatory lipid and oxylipin plasma profile. J Lipid Res (2014) 0.82
Central GPR109A Activation Mediates Glutamate-Dependent Pressor Response in Conscious Rats. J Pharmacol Exp Ther (2015) 0.77
A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem (1957) 173.99
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med (2011) 15.30
Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet (1994) 9.13
GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell (2010) 8.69
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med (2001) 7.69
Regulation of phosphoinositide-specific phospholipase C. Annu Rev Biochem (2001) 6.42
Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem (1996) 4.63
A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA (1994) 4.38
Fish consumption and the 30-year risk of fatal myocardial infarction. N Engl J Med (1997) 4.27
Drug treatment of lipid disorders. N Engl J Med (1999) 3.86
Clofibrate and niacin in coronary heart disease. JAMA (1975) 3.39
Fish consumption and risk of sudden cardiac death. JAMA (1998) 3.06
Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. J Lipid Res (2000) 2.70
Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem (2003) 2.52
Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med (2005) 2.40
The composition of food consumed by Greenland Eskimos. Acta Med Scand (1976) 2.27
Molecular identification of nicotinic acid receptor. Biochem Biophys Res Commun (2003) 2.00
GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest (2005) 1.88
Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr (2000) 1.77
Docosahexaenoic acid is a strong inhibitor of prostaglandin but not leukotriene biosynthesis. Proc Natl Acad Sci U S A (1983) 1.67
Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake. Circulation (2005) 1.56
GPI-microdomains: a role in signalling via immunoreceptors. Immunol Today (1999) 1.50
Modulation of dihydropyridine-sensitive calcium channels in heart cells by fish oil fatty acids. Proc Natl Acad Sci U S A (1992) 1.50
Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins (1989) 1.49
Langerhans cells release prostaglandin D2 in response to nicotinic acid. J Invest Dermatol (2006) 1.49
Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans. Ann Intern Med (1994) 1.45
Fatty acid substrate specificities of human prostaglandin-endoperoxide H synthase-1 and -2. Formation of 12-hydroxy-(9Z, 13E/Z, 15Z)- octadecatrienoic acids from alpha-linolenic acid. J Biol Chem (1995) 1.45
Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A (2006) 1.44
Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol (2008) 1.43
Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk (1999) 1.40
Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells. Mol Pharmacol (2006) 1.39
Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol (1998) 1.28
Docosahexaenoic acid affects cell signaling by altering lipid rafts. Reprod Nutr Dev (2005) 1.23
Nicotinic acid treatment of hypercholesteremia. Comparison of plain and sustained-action preparations and report of two cases of jaundice. JAMA (1961) 1.19
Niacin therapy in atherosclerosis. Curr Opin Lipidol (2004) 1.16
Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol (2002) 1.15
Tolerance to nicotinic acid flushing. Clin Pharmacol Ther (1991) 1.15
Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis (2007) 1.13
Single point mutations affect fatty acid block of human myocardial sodium channel alpha subunit Na+ channels. Proc Natl Acad Sci U S A (2001) 1.13
Soluble cell adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesion. Arterioscler Thromb Vasc Biol (1998) 1.08
Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest (1979) 1.06
n-3 fatty acids and lipoproteins: comparison of results from human and animal studies. Lipids (1996) 1.04
Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation. Int J Clin Pharmacol Ther (2007) 0.99
Modulation of lipid rafts by Omega-3 fatty acids in inflammation and cancer: implications for use of lipids during nutrition support. Nutr Clin Pract (2007) 0.98
Fatty acids and immune responses--a new perspective in searching for clues to mechanism. Annu Rev Nutr (2000) 0.97
Nicotinic acid induces secretion of prostaglandin D2 in human macrophages: an in vitro model of the niacin flush. Atherosclerosis (2006) 0.97
Modulation of enzymatic activities by n-3 polyunsaturated fatty acids to support cardiovascular health. J Nutr Biochem (2007) 0.96
A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin. Clin Cardiol (2003) 0.94
Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia. Am J Health Syst Pharm (2007) 0.93
The mechanism and mitigation of niacin-induced flushing. Int J Clin Pract (2009) 0.92
Prostaglandins contribute to the vasodilation induced by nicotinic acid. Prostaglandins (1979) 0.92
Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study. Curr Med Res Opin (2006) 0.91
Low-Dose Aspirin and Ibuprofen Reduce the Cutaneous Reactions Following Niacin Administration. Am J Ther (1995) 0.90
Dissociation of the effects of nicotinic acid on vasodilatation and lipolysis by a prostaglandin synthesis inhibitor, indomethacin, in man. Med Biol (1979) 0.90
Niacin-induced "flush" involves release of prostaglandin D2 from mast cells and serotonin from platelets: evidence from human cells in vitro and an animal model. J Pharmacol Exp Ther (2008) 0.88
Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia. Vasc Health Risk Manag (2009) 0.87
What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush? Curr Opin Lipidol (2009) 0.85
Increased compliance of niceritrol treatment by addition of aspirin: relationship between changes in prostaglandins and skin flushing. Int J Clin Pharmacol Ther Toxicol (1987) 0.84
G protein-coupled receptor for nicotinic acid in mouse macrophages. Biochem Pharmacol (2002) 0.84
Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study. J Clin Lipidol (2008) 0.84
Inhibition by docosahexaenoic acid of receptor-mediated Ca(2+) influx in rat vascular smooth muscle cells stimulated with 5-hydroxytryptamine. Eur J Pharmacol (2001) 0.84
Effects of docosahexaenoic acid on calcium pathway in adult rat cardiomyocytes. Life Sci (2002) 0.83
An improved method for determining medium- and long-chain FAMEs using gas chromatography. Lipids (2010) 0.83
Palmitic acid and linoleic acid metabolism in Caco-2 cells: different triglyceride synthesis and lipoprotein secretion. J Lipid Res (1995) 0.83
Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia. Am J Cardiovasc Drugs (2009) 0.83
Effect of lipid-lowering drug therapy on small-dense low-density lipoprotein. Ann Pharmacother (2005) 0.80
Effects of nicotinic acid on serum cholesterol concentrations of high density lipoprotein subfractions HDL2 and HDL3 in hyperlipoproteinaemia. J Intern Med (1990) 0.78
Cytosolic phospholipase A2 is responsible for prostaglandin E2 and leukotriene B4 formation in phagocyte-like PLB-985 cells: studies of differentiated cPLA2-deficient PLB-985 cells. J Leukoc Biol (2004) 0.78
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 10.24
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2012) 7.94
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2012) 6.94
2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation (2013) 5.02
2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 3.63
2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg (2014) 3.59
A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet (2012) 3.20
Nasopharyngeal carcinoma--review of the molecular mechanisms of tumorigenesis. Head Neck (2008) 2.28
SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci U S A (2003) 2.12
Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res (2004) 2.09
Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. Oncogene (2005) 2.06
Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene (2003) 1.93
Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene (2004) 1.93
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2012) 1.80
Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 1.79
Wnt signaling in lung cancer. Cancer Lett (2005) 1.77
An antagonist of dishevelled protein-protein interaction suppresses beta-catenin-dependent tumor cell growth. Cancer Res (2007) 1.73
Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of beta-catenin. Cancer Res (2003) 1.70
Assessing proarrhythmic potential of drugs when optimal studies are infeasible. Am Heart J (2009) 1.66
An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth. Cancer Res (2004) 1.64
A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia (2004) 1.54
Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma. Oncogene (2004) 1.52
c-Kit is not expressed in malignant mesothelioma. Mod Pathol (2003) 1.49
Heart rate-corrected QT interval in men increases during winter months. Heart Rhythm (2006) 1.48
Dickkopf-1 antagonizes Wnt signaling independent of beta-catenin in human mesothelioma. Biochem Biophys Res Commun (2004) 1.31
A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs (2008) 1.30
Inhibition of Wnt-1 signaling induces apoptosis in beta-catenin-deficient mesothelioma cells. Cancer Res (2004) 1.22
Cul4A is an oncogene in malignant pleural mesothelioma. J Cell Mol Med (2011) 1.21
Inhibition of Wnt16 in human acute lymphoblastoid leukemia cells containing the t(1;19) translocation induces apoptosis. Oncogene (2005) 1.20
SU1498, an inhibitor of vascular endothelial growth factor receptor 2, causes accumulation of phosphorylated ERK kinases and inhibits their activity in vivo and in vitro. J Biol Chem (2003) 1.18
Oleic and docosahexaenoic acid differentially phase separate from lipid raft molecules: a comparative NMR, DSC, AFM, and detergent extraction study. Biophys J (2004) 1.16
Omega-3 polyunsaturated fatty acids attenuate breast cancer growth through activation of a neutral sphingomyelinase-mediated pathway. Int J Cancer (2005) 1.15
Usefulness of fragmented QRS on a 12-lead electrocardiogram in acute coronary syndrome for predicting mortality. Am J Cardiol (2009) 1.15
Secreted frizzled-related protein 4 is silenced by hypermethylation and induces apoptosis in beta-catenin-deficient human mesothelioma cells. Cancer Res (2005) 1.11
Inhibition of Wnt-2 and galectin-3 synergistically destabilizes beta-catenin and induces apoptosis in human colorectal cancer cells. Int J Cancer (2007) 1.08
Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma. Biochem Biophys Res Commun (2006) 1.08
Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. Mol Cancer Ther (2002) 1.07
Cloning and characterization of a functional promoter of the human SOCS-3 gene. Biochem Biophys Res Commun (2003) 1.07
Efficacy of Wnt-1 monoclonal antibody in sarcoma cells. BMC Cancer (2005) 1.05
A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance. Am J Respir Cell Mol Biol (2005) 1.04
High ACAT1 expression in estrogen receptor negative basal-like breast cancer cells is associated with LDL-induced proliferation. Breast Cancer Res Treat (2009) 1.03
Wnt inhibitory factor inhibits lung cancer cell growth. J Thorac Cardiovasc Surg (2007) 1.03
Migration of MDA-MB-231 breast cancer cells depends on the availability of exogenous lipids and cholesterol esterification. Clin Exp Metastasis (2011) 1.03
Promoter demethylation of WIF-1 by epigallocatechin-3-gallate in lung cancer cells. Anticancer Res (2009) 1.02
Wnt inhibitory factor-1 gene transfer inhibits melanoma cell growth. Hum Gene Ther (2007) 1.02
Inhibition of CK2α down-regulates Notch1 signalling in lung cancer cells. J Cell Mol Med (2013) 1.01
Lidocaine-induced Brugada syndrome phenotype linked to a novel double mutation in the cardiac sodium channel. Circ Res (2008) 1.00
Inhibition of CK2α down-regulates Hedgehog/Gli signaling leading to a reduction of a stem-like side population in human lung cancer cells. PLoS One (2012) 0.99
Cloning and characterization of the promoter of human Wnt inhibitory factor-1. Biochem Biophys Res Commun (2004) 0.99
Long-chain saturated fatty acids induce pro-inflammatory responses and impact endothelial cell growth. Clin Nutr (2009) 0.99
The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma. J Pathol (2011) 0.98
Modulation of lipid rafts by Omega-3 fatty acids in inflammation and cancer: implications for use of lipids during nutrition support. Nutr Clin Pract (2007) 0.98
Organic cation transporters modulate the uptake and cytotoxicity of picoplatin, a third-generation platinum analogue. Mol Cancer Ther (2010) 0.96
Oleic acid inhibits stearic acid-induced inhibition of cell growth and pro-inflammatory responses in human aortic endothelial cells. J Lipid Res (2010) 0.96
Modulation of enzymatic activities by n-3 polyunsaturated fatty acids to support cardiovascular health. J Nutr Biochem (2007) 0.96
Omega-3 polyunsaturated fatty acids down-modulate CXCR4 expression and function in MDA-MB-231 breast cancer cells. Mol Cancer Res (2009) 0.96
Wnt signaling activation and WIF-1 silencing in nasopharyngeal cancer cell lines. Biochem Biophys Res Commun (2006) 0.95
Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 9: Arrhythmias and Conduction Defects: A Scientific Statement From the American Heart Association and American College of Cardiology. J Am Coll Cardiol (2015) 0.94
Epigenetic alteration of the Wnt inhibitory factor-1 promoter occurs early in the carcinogenesis of Barrett's esophagus. Cancer Sci (2007) 0.93
Surgery for Aortic Dilatation in Patients With Bicuspid Aortic Valves: A Statement of Clarification From the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation (2015) 0.93
Trans fatty acids and coronary heart disease. Nutr Clin Pract (2006) 0.92
Wnt2 as a new therapeutic target in malignant pleural mesothelioma. Int J Cancer (2005) 0.92
Wnt-1 signal as a potential cancer therapeutic target. Drug News Perspect (2006) 0.92
Frizzled-8 receptor is activated by the Wnt-2 ligand in non-small cell lung cancer. BMC Cancer (2013) 0.91
n-3 fatty acids prevent whereas trans-fatty acids induce vascular inflammation and sudden cardiac death. Br J Nutr (2009) 0.91
Diverse signaling pathways regulate fibroblast differentiation and transformation through Rho kinase activation. J Cell Physiol (2007) 0.90
Steroidal compounds in commercial parenteral lipid emulsions. Nutrients (2012) 0.89
Docosahexaenoic acid: a natural powerful adjuvant that improves efficacy for anticancer treatment with no adverse effects. Biofactors (2011) 0.89
Attenuation of proteolysis and muscle wasting by curcumin c3 complex in MAC16 colon tumour-bearing mice. Br J Nutr (2009) 0.89
Genomic alterations in human mesothelioma including high resolution mapping of common regions of DNA loss in chromosome arm 6q. Anticancer Res (2003) 0.88
Role of Rho kinase in sphingosine 1-phosphate-mediated endothelial and smooth muscle cell migration and differentiation. Mol Cell Biochem (2010) 0.88
Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 10: The Cardiac Channelopathies: A Scientific Statement From the American Heart Association and American College of Cardiology. J Am Coll Cardiol (2015) 0.88
Procaine and procainamide inhibit the Wnt canonical pathway by promoter demethylation of WIF-1 in lung cancer cells. Oncol Rep (2009) 0.87
Identification and cleavage site analysis of DNA sequences bound strongly by bleomycin. J Am Chem Soc (2009) 0.87
Lung tumourigenesis in a conditional Cul4A transgenic mouse model. J Pathol (2014) 0.86
Targeting the Wnt signaling pathway with dishevelled and cisplatin synergistically suppresses mesothelioma cell growth. Anticancer Res (2008) 0.86
Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes (2013) 0.86
Stathmin is overexpressed in malignant mesothelioma. Anticancer Res (2007) 0.86
Characterization of synergistic anti-cancer effects of docosahexaenoic acid and curcumin on DMBA-induced mammary tumorigenesis in mice. BMC Cancer (2013) 0.85
A synergistic antiproliferation effect of curcumin and docosahexaenoic acid in SK-BR-3 breast cancer cells: unique signaling not explained by the effects of either compound alone. BMC Cancer (2011) 0.85
Transgenic mice for cre-inducible overexpression of the Cul4A gene. Genesis (2011) 0.84
Acyl chain unsaturation in PEs modulates phase separation from lipid raft molecules. Biochem Biophys Res Commun (2003) 0.84
A novel 2,6-diisopropylphenyl-docosahexaenoamide conjugate induces apoptosis in T cell acute lymphoblastic leukemia cell lines. Biochem Biophys Res Commun (2011) 0.83
Protecting the heart of the American athlete: proceedings of the American College of Cardiology Sports and Exercise Cardiology Think Tank October 18, 2012, Washington, DC. J Am Coll Cardiol (2014) 0.83